PEXEVA Drug Patent Profile
✉ Email this page to a colleague
When do Pexeva patents expire, and when can generic versions of Pexeva launch?
Pexeva is a drug marketed by Sebela Ireland Ltd and is included in one NDA. There is one patent protecting this drug.
This drug has forty patent family members in twenty-five countries.
The generic ingredient in PEXEVA is paroxetine mesylate. There are thirty drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the paroxetine mesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Pexeva
A generic version of PEXEVA was approved as paroxetine mesylate by ACTAVIS LABS FL INC on June 20th, 2017.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PEXEVA?
- What are the global sales for PEXEVA?
- What is Average Wholesale Price for PEXEVA?
Summary for PEXEVA
| International Patents: | 40 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 19 |
| Clinical Trials: | 1 |
| Patent Applications: | 176 |
| Drug Prices: | Drug price information for PEXEVA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for PEXEVA |
| What excipients (inactive ingredients) are in PEXEVA? | PEXEVA excipients list |
| DailyMed Link: | PEXEVA at DailyMed |
Recent Clinical Trials for PEXEVA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Sheppard Pratt Health System | N/A |
| Central Michigan University | N/A |
US Patents and Regulatory Information for PEXEVA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sebela Ireland Ltd | PEXEVA | paroxetine mesylate | TABLET;ORAL | 021299-001 | Jul 3, 2003 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Sebela Ireland Ltd | PEXEVA | paroxetine mesylate | TABLET;ORAL | 021299-004 | Jul 3, 2003 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Sebela Ireland Ltd | PEXEVA | paroxetine mesylate | TABLET;ORAL | 021299-002 | Jul 3, 2003 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Sebela Ireland Ltd | PEXEVA | paroxetine mesylate | TABLET;ORAL | 021299-003 | Jul 3, 2003 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PEXEVA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sebela Ireland Ltd | PEXEVA | paroxetine mesylate | TABLET;ORAL | 021299-001 | Jul 3, 2003 | ⤷ Sign Up | ⤷ Sign Up |
| Sebela Ireland Ltd | PEXEVA | paroxetine mesylate | TABLET;ORAL | 021299-002 | Jul 3, 2003 | ⤷ Sign Up | ⤷ Sign Up |
| Sebela Ireland Ltd | PEXEVA | paroxetine mesylate | TABLET;ORAL | 021299-003 | Jul 3, 2003 | ⤷ Sign Up | ⤷ Sign Up |
| Sebela Ireland Ltd | PEXEVA | paroxetine mesylate | TABLET;ORAL | 021299-004 | Jul 3, 2003 | ⤷ Sign Up | ⤷ Sign Up |
| Sebela Ireland Ltd | PEXEVA | paroxetine mesylate | TABLET;ORAL | 021299-004 | Jul 3, 2003 | ⤷ Sign Up | ⤷ Sign Up |
| Sebela Ireland Ltd | PEXEVA | paroxetine mesylate | TABLET;ORAL | 021299-003 | Jul 3, 2003 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for PEXEVA
See the table below for patents covering PEXEVA around the world.
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
